Posted by Michael Wonder on 01 Jun 2020
Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease
1 June 2020 - New Brilinta indication expands treatment to high-risk coronary patients without a history of stroke or heart attack.
AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease, the most common type of heart disease.
The approval by the US FDA was based on positive results from the Phase III THEMIS trial.
